Background: Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide. Assessment of liver fibrosis (LF) via the utilization of noninvasive tests (NITs) has been emerging nowadays. These NITs as FIB-4 and FIB-5 have adequate predictive positive value (PPV) for diagnosis of nil or minimal fibrosis up to advanced fibrosis.
Aim of the work: Detect fibrosis regression after HCV treatment and HBV suppression using FIB-5 score and evaluation of the accuracy of FIB-5 score as a validated NIT of fibrosis compared to FIB-4.
Patients and methods: This is a prospective study on 100 patients with chronic hepatitis, 50 HCV patients who received direct acting anti-viral drugs (DAAs) about 5 years ago and achieved sustained virological response (SVR) and 50 HBV patients with undetected viremia and still on treatment according to the national program for treatment of HCV and Egyptian guidelines for HBV treatment respectively.
Results: Sensitivity and specificity test for FIB-5 level post-treatment in diagnosis of fibrosis regression in HCV patients were (88.2%, and 63.6% respectively) at cutoff value -14.695. Sensitivity and specificity test for FIB-5 level post-treatment in diagnosis of fibrosis regression in HBV patients were (57.1%, and 94.4% respectively) at cutoff value -8.68.
Conclusion: FIB-5 is both specific and sensitive test to assess fibrosis regression in chronic hepatitis patients after and on treatment.
Keywords: chronic liver disease; liver fibrosis; cirrhosis; FIB-4; FIB-5